Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Morning! Hope your blood sugar is normalizing after a feastful holiday. Today, we probe Vinay Prasad’s “extraordinary” email to CBER staffers about vaccines, discuss the fallout pharmacies may face from Medicare negotiations, and more.

The need-to-know this morning

Regeneron Pharmaceuticals and Tessera Therapeutics have signed a partnership agreement to co-develop Tessera’s experimental gene-editing treatment for alpha-1 antitrypsin deficiency (AATD), an inherited disease that affects the lungs and liver.

Novocure CEO Ashley Cordovo resigned and is being replaced by current president Frank Leonard.

Belite Bio said its oral treatment called tinlareba

See Full Page